News | May 05, 2023
Nouscom reaches clinical phase II using ProBioGen’s AGE1.CR.pIX production platform
Nous-209 has been developed using the Nouscom's viral vector platform
Nous-209 has been developed using the Nouscom's viral vector platform
China recorded unprecedented improvement in its API manufacturing score in the 2022 end of year CPHI Survey
Apollo continues to invest in genomics technology and research for better patient care
Gafchromic films support patient care in oncology
It provides doctors with three indicators: identification of the bone, confirmation of device insertion into the bone, and notification in case of perforation through the opposite end of the bone
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma
For the year 2022, Biocon bettered its score in all the four EcoVadis themes – Environment (70), Labor & Human Rights (70), Ethics (60), and Sustainable Procurement (60)
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
All children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including independent walking
The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022
Subscribe To Our Newsletter & Stay Updated
